A trial to determine incidence and risk for hyperlipidemia occurrence in insured patients receiving dasatinib or nilotinib for chronic myelogenous leukemia (CML)

Trial Profile

A trial to determine incidence and risk for hyperlipidemia occurrence in insured patients receiving dasatinib or nilotinib for chronic myelogenous leukemia (CML)

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Jul 2016

At a glance

  • Drugs Dasatinib (Primary) ; Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Jul 2016 New trial record
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top